Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mylan Labs -- Ignore unavailable to you. Want to Upgrade?

To: rhoffman who wrote (359)	9/11/1998 10:29:00 AM
From: Rande Is	Respond to of 384

Bob was last seen with Monica. MYL has a good future, IMO despite the impending global deflationary depression. Consumers on name brand drugs cannot stop taking them, but they CAN switch to the cheaper generic version [Mylan]. Also, the deflationary pressures here and overseas means that raw materials [chemicals] will be cheaper. The big name companies will no doubt maintain their current high prices and increase their margins, as they have recently shown. Whereas Mylan could pass some of that deflationary savings on to the customer and increase their market share and edge. Of all the drug stocks, Mylan looks the best heading into the rough seas ahead. Now by all means...if you do not believe the economists predictions concerning the economy, then please disregard the above. Rande Is